Cargando…

Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections

Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of M. tuberculosis (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeutic options are urgently needed...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Matteo, Stelitano, Giovanni, Griego, Anna, Chiarelli, Laurent R., Cazzaniga, Giulia, Gelain, Arianna, Pini, Elena, Camera, Marina, Canzano, Paola, Fumagalli, Andrea, Scarpa, Edoardo, Cordiglieri, Chiara, Rizzello, Loris, Villa, Stefania, Meneghetti, Fiorella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413995/
https://www.ncbi.nlm.nih.gov/pubmed/36015139
http://dx.doi.org/10.3390/ph15080992
_version_ 1784775886222917632
author Mori, Matteo
Stelitano, Giovanni
Griego, Anna
Chiarelli, Laurent R.
Cazzaniga, Giulia
Gelain, Arianna
Pini, Elena
Camera, Marina
Canzano, Paola
Fumagalli, Andrea
Scarpa, Edoardo
Cordiglieri, Chiara
Rizzello, Loris
Villa, Stefania
Meneghetti, Fiorella
author_facet Mori, Matteo
Stelitano, Giovanni
Griego, Anna
Chiarelli, Laurent R.
Cazzaniga, Giulia
Gelain, Arianna
Pini, Elena
Camera, Marina
Canzano, Paola
Fumagalli, Andrea
Scarpa, Edoardo
Cordiglieri, Chiara
Rizzello, Loris
Villa, Stefania
Meneghetti, Fiorella
author_sort Mori, Matteo
collection PubMed
description Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of M. tuberculosis (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeutic options are urgently needed. An attractive target for the development of new anti-TB agents is the salicylate synthase MbtI, the first enzyme of the mycobacterial siderophore biochemical machinery, absent in human cells. In this work, a set of analogues of 5-(3-cyanophenyl)furan-2-carboxylic acid (I), the most potent MbtI inhibitor identified to date, was synthesized, characterized, and tested to further elucidate the structural requirements for achieving an efficient MbtI inhibition and potent antitubercular activity. The structure–activity relationships (SAR) discussed herein evidenced the importance of the side chain linked to the phenyl moiety to improve the in vitro antimycobacterial activity. In detail, 1f emerged as the most effective analogue against the pathogen, acting without cytotoxicity issues. To deepen the understanding of its mechanism of action, we established a fluorescence-based screening test to quantify the pathogen infectivity within host cells, using MPI-2 murine cells, a robust surrogate for alveolar macrophages. The set-up of the new assay demonstrates significant potential to accelerate the discovery of new anti-TB drugs.
format Online
Article
Text
id pubmed-9413995
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94139952022-08-27 Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections Mori, Matteo Stelitano, Giovanni Griego, Anna Chiarelli, Laurent R. Cazzaniga, Giulia Gelain, Arianna Pini, Elena Camera, Marina Canzano, Paola Fumagalli, Andrea Scarpa, Edoardo Cordiglieri, Chiara Rizzello, Loris Villa, Stefania Meneghetti, Fiorella Pharmaceuticals (Basel) Article Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of M. tuberculosis (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeutic options are urgently needed. An attractive target for the development of new anti-TB agents is the salicylate synthase MbtI, the first enzyme of the mycobacterial siderophore biochemical machinery, absent in human cells. In this work, a set of analogues of 5-(3-cyanophenyl)furan-2-carboxylic acid (I), the most potent MbtI inhibitor identified to date, was synthesized, characterized, and tested to further elucidate the structural requirements for achieving an efficient MbtI inhibition and potent antitubercular activity. The structure–activity relationships (SAR) discussed herein evidenced the importance of the side chain linked to the phenyl moiety to improve the in vitro antimycobacterial activity. In detail, 1f emerged as the most effective analogue against the pathogen, acting without cytotoxicity issues. To deepen the understanding of its mechanism of action, we established a fluorescence-based screening test to quantify the pathogen infectivity within host cells, using MPI-2 murine cells, a robust surrogate for alveolar macrophages. The set-up of the new assay demonstrates significant potential to accelerate the discovery of new anti-TB drugs. MDPI 2022-08-11 /pmc/articles/PMC9413995/ /pubmed/36015139 http://dx.doi.org/10.3390/ph15080992 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mori, Matteo
Stelitano, Giovanni
Griego, Anna
Chiarelli, Laurent R.
Cazzaniga, Giulia
Gelain, Arianna
Pini, Elena
Camera, Marina
Canzano, Paola
Fumagalli, Andrea
Scarpa, Edoardo
Cordiglieri, Chiara
Rizzello, Loris
Villa, Stefania
Meneghetti, Fiorella
Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
title Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
title_full Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
title_fullStr Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
title_full_unstemmed Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
title_short Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
title_sort synthesis and assessment of the in vitro and ex vivo activity of salicylate synthase (mbti) inhibitors as new candidates for the treatment of mycobacterial infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413995/
https://www.ncbi.nlm.nih.gov/pubmed/36015139
http://dx.doi.org/10.3390/ph15080992
work_keys_str_mv AT morimatteo synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT stelitanogiovanni synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT griegoanna synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT chiarellilaurentr synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT cazzanigagiulia synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT gelainarianna synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT pinielena synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT cameramarina synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT canzanopaola synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT fumagalliandrea synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT scarpaedoardo synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT cordiglierichiara synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT rizzelloloris synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT villastefania synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections
AT meneghettifiorella synthesisandassessmentoftheinvitroandexvivoactivityofsalicylatesynthasembtiinhibitorsasnewcandidatesforthetreatmentofmycobacterialinfections